{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis%C2%AE", "query": { "intervention": "Restasis®" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 69, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Restasis%C2%AE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T19:03:27.293Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02328755", "title": "Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "peg-IFN-α", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplant (HCT)", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2015-01", "completion_date": "2019-03-25", "has_results": true, "last_update_posted_date": "2021-10-06", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02328755" }, { "nct_id": "NCT00806598", "title": "Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Aplastic Anemia" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 53, "start_date": "2005-05", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2013-03-12", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806598" }, { "nct_id": "NCT03657342", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2019-03-26", "completion_date": "2024-04-16", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657342" }, { "nct_id": "NCT07025811", "title": "A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dry Eye Disease" ], "interventions": [ { "name": "Vevye®", "type": "DRUG" }, { "name": "Xiidra®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 378, "start_date": "2025-07-09", "completion_date": "2026-07-16", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 8, "location_summary": "Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Andover", "state": "Massachusetts" }, { "city": "Garner", "state": "North Carolina" }, { "city": "Shelby", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07025811" }, { "nct_id": "NCT05293509", "title": "Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stem Cell Transplantation" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide (Cy)", "type": "DRUG" }, { "name": "Tacrolimus (or cyclosporine)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Rabbit ATG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-03-02", "completion_date": "2023-09-18", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293509" }, { "nct_id": "NCT00833495", "title": "Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allergic Conjunctivitis" ], "interventions": [ { "name": "Prednisolone Acetate 0.12% (Pred Mild®)", "type": "DRUG" }, { "name": "FOV1101-00", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% (Pred Forte®)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fovea Pharmaceuticals SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2009-01", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-03-09", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833495" }, { "nct_id": "NCT01064830", "title": "Topical Cyclosporine Suspension for the Treatment of Brittle Nails", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brittle Nail Syndrome" ], "interventions": [ { "name": "topical cyclosporine ophthalmic suspension 0.05%", "type": "DRUG" }, { "name": "vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2010-02", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2017-03-13", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064830" }, { "nct_id": "NCT00412360", "title": "Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelodysplastic Syndrome", "Natural Killer Cell Lymphoblastic Leukemia/Lymphoma" ], "interventions": [ { "name": "Single Umbilical Cord Blood Unit Transplant", "type": "BIOLOGICAL" }, { "name": "Double Umbilical Cord Blood Unit Transplant", "type": "BIOLOGICAL" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclosporine A", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 224, "start_date": "2006-12", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412360" }, { "nct_id": "NCT00040846", "title": "Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Phase Chronic Myelogenous Leukemia", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Peripheral T-cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Progressive Hairy Cell Leukemia, Initial Treatment", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Splenic Marginal Zone Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Childhood Anaplastic Large Cell Lymphoma", "Stage I Childhood Large Cell Lymphoma", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage I Small Lymphocytic Lymphoma", "Stage II Childhood Anaplastic Large Cell Lymphoma", "Stage II Childhood Large Cell Lymphoma", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Childhood Anaplastic Large Cell Lymphoma", "Stage III Childhood Large Cell Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Childhood Anaplastic Large Cell Lymphoma", "Stage IV Childhood Large Cell Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "74 Years", "sex": "ALL", "summary": "Up to 74 Years" }, "enrollment_count": 60, "start_date": "2001-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 6, "location_summary": "Denver, Colorado • Salt Lake City, Utah • Seattle, Washington + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040846" }, { "nct_id": "NCT00611403", "title": "Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dry Eye Syndromes" ], "interventions": [ { "name": "Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)", "type": "DRUG" }, { "name": "Artificial Tears REFRESH ENDURA®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "21 Years to 50 Years" }, "enrollment_count": 137, "start_date": "2007-12", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2011-12-20", "last_synced_at": "2026-09-02T19:03:27.293Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00611403" } ] }